Skip to main content

Neurocrine (NBIX) Receives a Buy from Canaccord Genuity

Tipranks - Tipranks - Fri Dec 19, 2025

Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Neurocrine yesterday and set a price target of $164.00. The company’s shares closed yesterday at $141.70.

Claim 50% Off TipRanks Premium and Invest with Confidence

Kulkarni covers the Healthcare sector, focusing on stocks such as Neurocrine, ATAI Life Sciences, and Biogen. According to TipRanks, Kulkarni has an average return of 7.2% and a 44.61% success rate on recommended stocks.

In addition to Canaccord Genuity, Neurocrine also received a Buy from Truist Financial’s Danielle Brill in a report issued yesterday. However, on December 12, Mizuho Securities maintained a Hold rating on Neurocrine (NASDAQ: NBIX).

See today’s best-performing stocks on TipRanks >>

Based on Neurocrine’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $794.9 million and a net profit of $209.5 million. In comparison, last year the company earned a revenue of $622.1 million and had a net profit of $129.8 million

Read More on NBIX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).